News - Biotechnology, Licensing

Filter

Current filters:

BiotechnologyLicensing

Popular Filters

151 to 175 of 374 results

Transgene out-licenses skin cancer candidate TG1042 to Ascend Pharma

04-07-2013

French biotech firm Transgene SA (Euronext Paris: TNG) has granted Ascend Biopharmaceuticals, an emerging…

Ascend PharmaASN-002BiotechnologyLicensingOncologyTG1042Transgene

Pharming and SIPI collaboration includes Ruconest marketing in China

02-07-2013

Dutch biotech company Pharming Group (NYSE Euronext: PHARM) and Shanghai Institute of Pharmaceutical…

Asia-PacificBiotechnologyCardio-vascularLicensingPharmaceuticalPharmingResearchRuconestSinopharm Group

Immunocore and Genentech collaborate to develop ImmTACs for multiple cancer targets

01-07-2013

Immunocore, an Oxford, UK-based biotechnology company developing novel biological drugs known as ImmTACs…

BiotechnologyGenentechLicensingOncologyResearchRoche

Immune Design and Medicago link up to develop flu vaccines

01-07-2013

Privately-held US biotech firm Immune Design and Medicago (TSX: MDG), a Canadian biopharmaceutical company…

Anti-viralsBiotechnologyImmune DesignLicensingMedicagoVaccines

Seattle Genetics takes up option to co-develop additional ADC with Astellas

28-06-2013

Japanese drug major Astellas Pharma (TYO: 4503) says that US biotech firm Seattle Genetics (Nasdaq: SGEN)…

ASG-15MEAstellas PharmaBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

MorphoSys and Celgene in deal to advance MOR202 for multiple myeloma

27-06-2013

German biotech firm MorphoSys (FSE: MOR) and USA-based Celgene (Nasdaq: CELG), the world's largest independent…

BiotechnologyCelgeneEuropeLicensingMergers & AcquisitionsMOR202MorphoSysOncology

Bayer to spend up to $520 million on antibody drug conjugate deal with Seattle Genetics

26-06-2013

US biotech firm Seattle Genetics (Nasdaq: SGEN) says it has entered into a new antibody-drug conjugate…

BayerBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

Astellas and Cytokinetics collaborate on new frontier of muscle biology

26-06-2013

In a second deal announced this month by US biotech firm, Cytokinetics (Nasdaq: CYTK) has entered into…

Astellas PharmaBiotechnologyCK-2127107CytokineticsLicensingPharmaceuticalResearch

Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis

19-06-2013

Sweden-based Athera Biotechnologies, which is 65% owned by Karolinska Development, has entered into an…

Athera BiotechnologiesBiotechnologyBoehringer IngelheimCardio-vascularKarolinska DevelopmentLicensing

Genmab and ADC Thera link for antibody drug conjugate combining HuMax-TAC and PBD warhead

18-06-2013

Denmark's Genmab (OMX: GEN) and Switzerland-based ADC Therapeutics have entered an agreement to develop…

ADC TherapeuticsBiotechnologyGenmabHuMax-TACLicensingOncologyResearch

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research

17-06-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

Bristol-Myers and Simcere agree to co-develop/commercialize Orencia SC in China

14-06-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) and China-based Simcere Pharmaceutical (NYSE: SCR) have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyBristol-Myers SquibbLicensingOrenciaPharmaceuticalSimcere Pharmaceutical

Amgen and Cytokinetics expand omecamtiv mecarbil accord

12-06-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech company, has expanded its strategic…

AmgenAsia-PacificBiotechnologyCardio-vascularCytokineticsLicensingomecamtiv mecarbil

BioLineRx collaborates with Chinese firm on hep C drug BL-8030

11-06-2013

Israeli drug developer BioLineRx (TASE: BLRX) has signed an out-licensing agreement with Jiangsu Chia-tai…

Anti-viralsAsia-PacificBioLineRxBiotechnologyBL-8030Chia-tai Tianqing PharmaceuticalLicensingPharmaceutical

Life Sciences IPOs have biggest month - May - in 13 years, reports Burrill

07-06-2013

A total of eight life sciences companies went public on US exchanges in May, the busiest month for initial…

BiotechnologyFinancialLicensingMergers & AcquisitionsPharmaceutical

CytomX signs up to $635 million oncology deal with Pfizer

07-06-2013

US biotech firm CytomX Therapeutics, which is developing a new generation of targeted antibody therapeutics,…

BiotechnologyCytomX TherapeuticsLicensingOncologyPfizerPharmaceuticalResearch

Medigene secures SynCore as global partner for EndoTAG-1

02-06-2013

German biotech firm Medigene (MDG: GR) has secured SynCore Biotechnology (part of Taiwan's Sinphar Pharmaceutical…

BiotechnologyEndoTAG-1FinancialLicensingMedigeneSynCore Biotechnology

Merck Serono collaborates with China's BeiGene on second-generation BRAF Inhibitor

31-05-2013

Merck Serono, a division of Germany's Merck KGaA (MRK: DE), today (May 31) announced that it has signed…

BeiGeneBeiGene-283BiotechnologyLicensingMerck KGaAMerck SeronoOncologyPharmaceutical

Oncothyreon and Array collaborate on anti-HER2 compound ARRY-380

30-05-2013

US biotech firms Oncothyreon (Nasdaq: ONTY) and Array BioPharma (Nasdaq: ARRY) plan to collaborate on…

Array BioPharmaARRY-380BiotechnologyLicensingOncologyOncothyreonPharmaceuticalResearch

RedHill Biopharma views regulatory pathway for RHB-101 in CHF and hypertension

29-05-2013

Emerging Israeli biopharma company RedHill Biopharma (TASE: RDHL) says that it recently concluded a positive…

BiotechnologyCardio-vascularCarvedilolLicensingPharmaceuticalRedHill BiopharmaRegulationResearchRHB-101

Stallergenes and DBV Technologies partner on developing novel respiratory allergies treatments

20-05-2013

French biotech firms DBV Technologies (Euronext: DBV), creator of Viaskin, a new standard in the treatment…

BiotechnologyDBV TechnologiesLicensingResearchRespiratory and PulmonaryStallergenes

Neovacs moving forward in rheumatoid arthritis, say analysts

17-05-2013

French biotech firm Neovacs (Alternext Paris: ALNEV) intends to initiate a Phase IIb trial with its lead…

Anti-Arthritics/RheumaticsBiotechnologyFinancialLicensingNeovacsResearch

CMC Biologics and RuiYi link on MAb; Deal for Cynviloq rights in EU

14-05-2013

Denmark and USA-based contract manufacturers CMC Biologics has entered into an agreement with China's…

Asia-PacificBiotechnologyCMC BiologicsCynviloqEuropeIGDRASOLLicensingOncologyPharmaceuticalResearchRuiYiSamyang BiopharmaceuticalsSorrento Therapeutics

151 to 175 of 374 results

Back to top